Last reviewed · How we verify
Ga-68 labeled PSMA-11 PET
Ga-68 labeled PSMA-11 is a positron emission tomography (PET) imaging agent that binds to prostate-specific membrane antigen (PSMA) on prostate cancer cells to enable detection and localization.
Ga-68 labeled PSMA-11 is a positron emission tomography (PET) imaging agent that binds to prostate-specific membrane antigen (PSMA) on prostate cancer cells to enable detection and localization. Used for Imaging of PSMA-positive lesions in men with prostate cancer, Detection of recurrent prostate cancer.
At a glance
| Generic name | Ga-68 labeled PSMA-11 PET |
|---|---|
| Also known as | Ga-68 labeled DKFZ-PSMA-11, Ga-68 labeled Glu-NH-CO-NH- Lys(Ahx)-HBED-CC, Ga-68 labeled Glu-urea- Lys(Ahx)-HBED-CC, Ga-68 labeled HBED-CC PSMA |
| Sponsor | University of California, San Francisco |
| Drug class | PET imaging agent |
| Target | PSMA (prostate-specific membrane antigen) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
PSMA-11 is a small-molecule ligand that targets prostate-specific membrane antigen, a transmembrane protein highly expressed on prostate cancer cells. When labeled with Gallium-68 (Ga-68), a positron-emitting radioisotope, it enables PET imaging to detect and visualize PSMA-positive lesions in patients with prostate cancer. This allows clinicians to identify primary tumors, metastases, and recurrent disease for staging and treatment planning.
Approved indications
- Imaging of PSMA-positive lesions in men with prostate cancer
- Detection of recurrent prostate cancer
Common side effects
- Radiation exposure
- Injection site reactions
Key clinical trials
- Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan (PHASE2)
- Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial (PHASE2)
- 68Ga-PSMA PET in the Renal Cell Carcinoma (NA)
- NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. (PHASE1)
- Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT) (PHASE2)
- COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P)
- A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC (PHASE2)
- The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ga-68 labeled PSMA-11 PET CI brief — competitive landscape report
- Ga-68 labeled PSMA-11 PET updates RSS · CI watch RSS
- University of California, San Francisco portfolio CI